Quick Answer
Lantern Pharma Inc. reported Cash And Cash Equivalents At Carrying Value of $4.42 million for the year ending 2025.
- Lantern Pharma Inc. showed a decrease of -41.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Lantern Pharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $1.43 million | Q3 2019: $1.94 million | Q4 2019: $1.23 million | Q1 2020: $634.2 thousand | Q2 2020: $23.80 million | Q3 2020: $20.80 million | Q1 2021: $81.37 million | Q2 2021: $61.35 million | Q3 2021: $54.67 million | Q1 2022: $46.65 million | Q2 2022: $43.36 million | Q3 2022: $39.26 million | Q1 2023: $32.48 million | Q2 2023: $28.42 million | Q3 2023: $25.57 million | Q1 2024: $18.36 million | Q2 2024: $12.98 million | Q3 2024: $8.10 million | Q1 2025: $6.38 million | Q2 2025: $6.06 million | Q3 2025: $8.39 million.
- Over the full 8 years of available data (2018 to 2025), Lantern Pharma Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 893.5%.
- Historical annual values: Fiscal year 2025: $4.42 million | Fiscal year 2024: $7.51 million | Fiscal year 2023: $21.94 million | Fiscal year 2022: $37.20 million | Fiscal year 2021: $51.52 million | Fiscal year 2020: $19.23 million | Fiscal year 2019: $1.23 million | Fiscal year 2018: $445.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: